Search Results - "Caligiuri, M.A."

Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target by Harb, J G, Neviani, P, Chyla, B J, Ellis, J J, Ferenchak, G J, Oaks, J J, Walker, C J, Hokland, P, Roy, D C, Caligiuri, M A, Marcucci, G, Huettner, C S, Perrotti, D

“…The dismal outcome of blast crisis chronic myelogenous leukemia (CML-BC) patients underscores the need for a better understanding of the mechanisms responsible…”
Get full text

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma by Chu, J, Deng, Y, Benson, D M, He, S, Hughes, T, Zhang, J, Peng, Y, Mao, H, Yi, L, Ghoshal, K, He, X, Devine, S M, Zhang, X, Caligiuri, M A, Hofmeister, C C, Yu, J

“…Multiple myeloma (MM) is an incurable hematological malignancy. Chimeric antigen receptor (CAR)-expressing T cells have been demonstrated successfully in the…”
Get full text

Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia by Park, I-K, Mundy-Bosse, B, Whitman, S P, Zhang, X, Warner, S L, Bearss, D J, Blum, W, Marcucci, G, Caligiuri, M A

“…In acute myeloid leukemia (AML), about 25–30% of patients harbor a constitutively active receptor tyrosine kinase (RTK) FLT3 encoded by a FLT3 allele harboring…”
Get full text

The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation by Tarighat, S S, Santhanam, R, Frankhouser, D, Radomska, H S, Lai, H, Anghelina, M, Wang, H, Huang, X, Alinari, L, Walker, A, Caligiuri, M A, Croce, C M, Li, L, Garzon, R, Li, C, Baiocchi, R A, Marcucci, G

“…Changes in the enzymatic activity of protein arginine methyltransferase (PRMT) 5 have been associated with cancer; however, the protein’s role in acute myeloid…”
Get full text

Interleukin-15 as a potential regulator of the innate immune response by Carson, W, Caligiuri, M A

“…Interleukin-15 (IL-15) is a newly-discovered cytokine that is produced by activated monocytes early in the course of the innate immune response. IL-15 is able…”
Get full text

Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia by Dorrance, A M, Neviani, P, Ferenchak, G J, Huang, X, Nicolet, D, Maharry, K S, Ozer, H G, Hoellarbauer, P, Khalife, J, Hill, E B, Yadav, M, Bolon, B N, Lee, R J, Lee, L J, Croce, C M, Garzon, R, Caligiuri, M A, Bloomfield, C D, Marcucci, G

“…Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the…”
Get full text

Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia by Khalife, J, Radomska, H S, Santhanam, R, Huang, X, Neviani, P, Saultz, J, Wang, H, Wu, Y-Z, Alachkar, H, Anghelina, M, Dorrance, A, Curfman, J, Bloomfield, C D, Medeiros, B C, Perrotti, D, Lee, L J, Lee, R J, Caligiuri, M A, Pichiorri, F, Croce, C M, Garzon, R, Guzman, M L, Mendler, J H, Marcucci, G

“…High levels of microRNA-155 ( miR-155 ) are associated with poor outcome in acute myeloid leukemia (AML). In AML, miR-155 is regulated by NF-κB, the activity…”
Get full text

Somatic mutational landscape of AML with inv(16) or t(8;21) identifies patterns of clonal evolution in relapse leukemia by Sood, R, Hansen, N F, Donovan, F X, Carrington, B, Bucci, D, Maskeri, B, Young, A, Trivedi, N S, Kohlschmidt, J, Stone, R M, Caligiuri, M A, Chandrasekharappa, S C, Marcucci, G, Mullikin, J C, Bloomfield, C D, Liu, P

Get full text

GAS6 expression identifies high-risk adult AML patients: potential implications for therapy by Whitman, S P, Kohlschmidt, J, Maharry, K, Volinia, S, Mrózek, K, Nicolet, D, Schwind, S, Becker, H, Metzeler, K H, Mendler, J H, Eisfeld, A-K, Carroll, A J, Powell, B L, Carter, T H, Baer, M R, Kolitz, J E, Park, I-K, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

“…Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic…”
Get full text

Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia by Mims, A, Walker, A R, Huang, X, Sun, J, Wang, H, Santhanam, R, Dorrance, A M, Walker, C, Hoellerbauer, P, Tarighat, S S, Chan, K K, Klisovic, R B, Perrotti, D, Caligiuri, M A, Byrd, J C, Chen, C-S, James Lee, L, Jacob, S, Mrózek, K, Bloomfield, C D, Blum, W, Garzon, R, Schwind, S, Marcucci, G

“…Histone deacetylase (HDAC) inhibitors either alone or in combination with hypomethylating agents have limited clinical effect in acute myeloid leukemia (AML)…”
Get full text

A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia by Metzeler, K H, Maharry, K, Kohlschmidt, J, Volinia, S, Mrózek, K, Becker, H, Nicolet, D, Whitman, S P, Mendler, J H, Schwind, S, Eisfeld, A-K, Wu, Y-Z, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Baer, M R, Carroll, A J, Stone, R M, Caligiuri, M A, Marcucci, G, Bloomfield, C D

“…Acute myeloid leukemia (AML) is hypothesized to be sustained by self-renewing leukemia stem cells (LSCs). Recently, gene expression signatures (GES) from…”
Get full text

Somatic mutational landscape of AML with inv identifies patterns of clonal evolution in relapse leukemia by Sood, R, Hansen, N.F, Donovan, F.X, Carrington, B, Bucci, D, Maskeri, B, Young, A, Trivedi, N.S, Kohlschmidt, J, Stone, R.M, Caligiuri, M.A, Chandrasekharappa, S.C, Marcucci, G, Mullikin, J.C, Bloomfield, C.D, Liu, P

Get full text

Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8 by Becker, H, Maharry, K, Mrózek, K, Volinia, S, Eisfeld, A-K, Radmacher, M D, Kohlschmidt, J, Metzeler, K H, Schwind, S, Whitman, S P, Mendler, J H, Wu, Y-Z, Nicolet, D, Paschka, P, Powell, B L, Carter, T H, Wetzler, M, Kolitz, J E, Carroll, A J, Baer, M R, Caligiuri, M A, Stone, R M, Marcucci, G, Bloomfield, C D

Get full text

Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML by Bernot, K M, Siebenaler, R F, Whitman, S P, Zorko, N A, Marcucci, G G, Santhanam, R, Ahmed, E H, Ngangana, M, McConnell, K K, Nemer, J S, Brook, D L, Kulp, S K, Chen, C S, Frankhouser, D, Yan, P, Bundschuh, R, Zhang, X, Dorrance, A M, Dickerson, K E, Jarjoura, D, Blum, W, Marcucci, G, Caligiuri, M A

Get full text

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720 by Baer, M R, George, S L, Sanford, B L, Mrózek, K, Kolitz, J E, Moore, J O, Stone, R M, Powell, B L, Caligiuri, M A, Bloomfield, C D, Larson, R A

“…Untreated de novo ( n =421) and secondary ( n =189) acute myeloid leukemia (AML) patients ⩾60 years received intensified chemotherapy, including daunorubicin…”
Get full text

The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia by Whitman, S P, Caligiuri, M A, Maharry, K, Radmacher, M D, Kohlschmidt, J, Becker, H, Mrózek, K, Wu, Y-Z, Schwind, S, Metzeler, K H, Mendler, J H, Wen, J, Baer, M R, Powell, B L, Carter, T H, Kolitz, J E, Wetzler, M, Carroll, A J, Larson, R A, Marcucci, G, Bloomfield, C D

Get full text

A phase I II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma by Woyach, J A, Lin, T S, Lucas, M S, Heerema, N, Moran, M E, Cheney, C, Lucas, D M, Wei, L, Caligiuri, M A, Byrd, J C

“…Rituximab has modest activity in relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma but is associated with tumor necrosis factor-α (TNF-α)…”
Get full text

Overexpression of the ERG Gene Is an Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B Study (CALGB) by Marcucci, Guido, Baldus, C.D., Ruppert, A.S., Radmacher, M.D., Mrózek, K., Whitman, S.P., Kolitz, J.E., Edwards, C.G., Vardiman, J.W., Powell, B.L., Baer, M.R., Moore, J.O., Perrotti, D., Caligiuri, M.A., Carroll, A.J., Larson, R.A., de la Chapelle, A., Bloomfield, C.D.

“…Around 45% of adults with AML have NC and are included in an intermediate-risk group. However, their 5-year (yr) overall survival (OS) rates vary between 24…”
Get full text

Independent Validation of Prognostic Relevance of a Previously Reported Gene-Expression Signature in Acute Myeloid Leukemia (AML) with Normal Cytogenetics (NC): A Cancer and Leukemia Group B (CALGB) Study by Marcucci, Guido, Radmacher, M.D., Ruppert, A.S., Mrózek, K., Kolitz, J.E., Whitman, S.P., Edwards, C.G., Vardiman, J.W., Caligiuri, M.A., Carroll, A.J., Larson, R.A., Bloomfield, C.D.

“…The heterogeneous clinical outcome of NC AML patients (pts), who constitute about 45% of AML pts and are assigned to an intermediate-risk category, likely…”
Get full text

High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein by Alexander, R.L, Ramage, J, Kucera, G.L, Caligiuri, M.A, Frankel, A.E

“…Diphtheria fusion proteins are a novel class of agents for the treatment of chemotherapy resistant AML. We prepared DT 388IL3 composed of human interleukin-3…”
Get full text